|
Name |
Zygosporin E
|
Molecular Formula | C30H37NO5 | |
IUPAC Name* |
[(2R,3E,5S,7R,9E,12S,14S,16S)-16-benzyl-12-hydroxy-5,7,14-trimethyl-13-methylidene-6,18-dioxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9-dien-2-yl] acetate
|
|
SMILES |
C[C@@H]1C/C=C/C2[C@@H](C(=C)[C@H](C3C2([C@@H](/C=C/[C@@H](C1=O)C)OC(=O)C)C(=O)N[C@H]3CC4=CC=CC=C4)C)O
|
|
InChI |
InChI=1S/C30H37NO5/c1-17-10-9-13-23-28(34)20(4)19(3)26-24(16-22-11-7-6-8-12-22)31-29(35)30(23,26)25(36-21(5)32)15-14-18(2)27(17)33/h6-9,11-15,17-19,23-26,28,34H,4,10,16H2,1-3,5H3,(H,31,35)/b13-9+,15-14+/t17-,18+,19-,23?,24+,25-,26?,28-,30?/m1/s1
|
|
InChIKey |
YOSIWRQXBHJIKL-KJRGTWELSA-N
|
|
Synonyms |
Zygosporin E; 26399-27-9
|
|
CAS | 26399-27-9 | |
PubChem CID | 121596711 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 491.6 | ALogp: | 3.7 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 92.7 | Aromatic Rings: | 4 |
Heavy Atoms: | 36 | QED Weighted: | 0.481 |
Caco-2 Permeability: | -4.755 | MDCK Permeability: | 0.00005660 |
Pgp-inhibitor: | 0.371 | Pgp-substrate: | 0.013 |
Human Intestinal Absorption (HIA): | 0.196 | 20% Bioavailability (F20%): | 0.032 |
30% Bioavailability (F30%): | 0.004 |
Blood-Brain-Barrier Penetration (BBB): | 0.798 | Plasma Protein Binding (PPB): | 91.49% |
Volume Distribution (VD): | 0.979 | Fu: | 10.95% |
CYP1A2-inhibitor: | 0.049 | CYP1A2-substrate: | 0.098 |
CYP2C19-inhibitor: | 0.618 | CYP2C19-substrate: | 0.29 |
CYP2C9-inhibitor: | 0.58 | CYP2C9-substrate: | 0.097 |
CYP2D6-inhibitor: | 0.281 | CYP2D6-substrate: | 0.27 |
CYP3A4-inhibitor: | 0.905 | CYP3A4-substrate: | 0.413 |
Clearance (CL): | 5.328 | Half-life (T1/2): | 0.035 |
hERG Blockers: | 0.146 | Human Hepatotoxicity (H-HT): | 0.798 |
Drug-inuced Liver Injury (DILI): | 0.282 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.779 | Maximum Recommended Daily Dose: | 0.974 |
Skin Sensitization: | 0.088 | Carcinogencity: | 0.132 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.972 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004026 | 0.802 | D0V3ZA | 0.254 | ||||
ENC005439 | 0.766 | D09NNH | 0.254 | ||||
ENC004341 | 0.766 | D0SP3D | 0.247 | ||||
ENC006059 | 0.766 | D01TSI | 0.247 | ||||
ENC002828 | 0.761 | D0W7RJ | 0.246 | ||||
ENC004745 | 0.752 | D0R1BD | 0.246 | ||||
ENC004468 | 0.737 | D06CWH | 0.245 | ||||
ENC003763 | 0.692 | D0A5LH | 0.243 | ||||
ENC005506 | 0.692 | D0OB1J | 0.241 | ||||
ENC005175 | 0.692 | D0IN7I | 0.241 |